Peripheral blood samples were collected and evaluated prospectively from subjects enrolled on the COG trial ASCT0031, a phase III randomized, placebo-controlled, double blind trial evaluating two treatment regimens for pediatric subjects with newly diagnosed extensive cGVHD as previously described [ 7].
A randomized, double blind, multicenter study evaluated 625 postmenopausal women with 3 doses of combined E2 and NETA compared to unopposed E2.
This phase I study was designed as a double blind study to evaluate safety and immunogenicity in a descriptive per total vaccinated subjects' analysis.
We conducted a randomized, placebo-controlled, double blind study to evaluate the need for pethidine in PBL.
Two double blind RCTs conducted evaluate the effect of R. rosea combined with other herbs on exercise performance [ 18, 21].
Currently, a large, randomized, placebo-controlled, double blind trial to evaluate the effect of RhEPO treatment (to achieve Hb levels of 13.0 g/dl) on cardiovascular events in anemic CKD patients (TREAT) is ongoing [ 4].
This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo.
Two double-blind RCTs evaluated acupressure for minor trauma pain during ambulance transport [ 36, 37].
This randomised, double-blind trial evaluated the haemodynamic effects of LS in low-risk patients (n = 23) following coronary artery bypass surgery.
In conclusion, this placebo-controlled, double-blind trial evaluated the safety and efficacy of a DPP-4 inhibitor exclusively in patients with type 2 diabetes and severe RI.
Two randomized, double-blind studies evaluated the efficacy and safety of palonosetron versus placebo in preventing post-operative nausea and vomiting (PONV).
